New York U.S. Congressional Delegation Sends Letter to PTO Head Michelle Lee

Ten members the U.S. House of Representatives from New York wrote to U.S. Patent and Trademark Office Director Michelle K. Lee to express concern with continued abuse of the inter partes review (IPR) system by financial speculators and other third parties with no legitimate interests in the patented technology

Neat, Plausible, and Wrong

Why the focus on intellectual property fails to address the complexities of medicinal access in India Stephen M. Sammut and Daniel S. Levine Released in San Francisco, June, 2016 Supported by and prepared for the Biotechnology Innovation Organization and the Association of Biotechnology Led Enterprises The opinions expressed in this paper are those of the authors and do not necessarily reflect the opinions of BIO and ABLE.

BIO Statement Regarding the UN High Level Panel on Access to Medicines Report

Sadly the United Nations High Level Panel ignored the real issues that impact or delay delivery of innovative treatments and cures throughout the developing world, while focusing on policy recommendations in the one area – intellectual property – that would actually undermine ongoing research and development by hundreds of companies, universities and researchers.  

The Patent Reform Act of 2007 - Coalition Letter

More than 430 organizations representing American innovation in a wide range of industries in all 50 states wrote Senate leaders to express continued concern with S. 1145.

BIO Testimony to the House Judiciary Committee Concerning the Hearing on Patent Reform

BIO 2016 Special 301 Submission

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission. 

BIO Comments on Draft Patents (Amendment) Rule 2015

The Biotechnology Industry Organization (BIO) greatly appreciates the opportunity to provide comments/suggestions of the stakeholders on the Draft Patents (Amendment) Rules 2015 published by the Ministry of Commerce & Industry.

BIO Comments on the July 2015 Update on Subject Matter Eligibility

The Biotechnology Industry Organization (BIO) appreciates this opportunity to submit comments on the United States Patent and Trademark Office’s (USPTO) July 2015 Update on Subject Matter Eligibility (Guidance).

BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership


BIO Statement Concerning the Recent Ruling Issued by the PTO’s Patent Trial and Appeal Board

"It is disappointing that the PTO’s Patent Trial and Appeal Board (PTAB) failed to properly assess the important issues raised by this motion. This cursory and erroneous ruling reinforces the immediate need for Congress and the PTO leadership to take clear and decisive action to prevent any further misuse and abuse of the Inter Partes Review process by hedge funds, extortionists and other questionable entities seeking to undermine it for their own financial benefit."